Introduction {#s1}
============

Poxviruses are cytoplasm-replicating large double-stranded DNA viruses. Two of the best-known members of the family of *Poxviridae* are variola virus, the causative agent of smallpox, and vaccinia viruses (VACV), the smallpox vaccine strain. Smallpox was declared eradicated in 1979 by the World Health Organization (WHO) following a long, global vaccination campaign [@pone.0060557-The1]. Despite smallpox eradication, studies on VACV remain relevant today. There is a continuing need for surveillance for potential smallpox outbreaks and bioterrorism acts using variola virus or other orthopoxviruses (OPVs) [@pone.0060557-Henderson1], [@pone.0060557-LevyBruhl1], [@pone.0060557-Mahalingam1]. Furthermore, VACV has been employed to develop effective monkeypox vaccines [@pone.0060557-Earl1], [@pone.0060557-Stittelaar1], [@pone.0060557-Earl2]. The most widely used smallpox vaccine strain in China is the Temple of Heaven strain (also known as the Tiantan strain or VACV-TT). Its comparative strains are EM-63 in Russia, Lister/Elstree in Europe, New York City Board of Health (NYCBH)/Dryvax/Wyeth in the United States [@pone.0060557-Fenner1]. The most frequently studied VACV strain is Western Reserve (WR), a mouse brain passaged derivative of NYCBH [@pone.0060557-Parker1], [@pone.0060557-Fulginiti1]. Virulence attenuation and immunogenicity improvement are important aspects of VACV based vaccine development [@pone.0060557-Earl2], [@pone.0060557-Belyakov1], [@pone.0060557-Weltzin1].

Currently, there are 30 VACV genomes stored in the Viral Bioinformatics Resource Center (<http://www.virology.ca>). Several reports have illustrated the presence of genomic diversity in these earlier generations of smallpox vaccines. Qin et al., sequenced 11 clones isolated from Dryvax and revealed the presence of genetic diversity, with deletions in the right-hand inverted terminal repeat (ITR) [@pone.0060557-Qin1]. Esposito et al., reported the presence of 573 single base polymorphisms and 53 insertions and deletions between the NYCBH/Dryvax clone Acam2000 and a more neurovirulent sister clone [@pone.0060557-Osborne1]. Garcel et al., showed that VACV-Lister also contained genotypic and phenotypic diversity [@pone.0060557-Garcel1] and shotgun sequencing of the genome of an unpurified Lister stock yielded more than 1,200 polymorphic sites [@pone.0060557-Morikawa1].

The original TT strain was previously reported to have been isolated from skin lesions of a Chinese individual with smallpox in 1926 and had an attenuation history of passages in monkey, rabbit, bovine skin and rabbit testis [@pone.0060557-Dong1]. TT had similar vaccination reaction characteristics as the contemporary Japanese cowpox strain and was used in the production of smallpox vaccine in China [@pone.0060557-Dong1], [@pone.0060557-Lu1], [@pone.0060557-Kai1]. Originally, the TT vaccine was prepared from skin lesion materials after intracutaneous inoculations in calves. From 1969, it was produced in chicken embryo fibroblasts (CEF) cells and the TT (752-1) was a viral batch produced in 1975. The genomic sequence of a TT vaccine stock was determined and submitted to GenBank (accession number AF095689.1) in 1998. It was subsequently recognized that several sequencing errors existed [@pone.0060557-Upton1]. Currently, an HIV candidate vaccine, rTV, uses TT as its vector [@pone.0060557-Liu1]. It had completed a Phase I clinical trial and began a Phase II trial in 2012 ([www.IAVI.org](http://www.IAVI.org)). In this study, we report the results from sequencing and virulence characterization of TT clones derived from TT (752-1).

Materials and Methods {#s2}
=====================

Cells, Viruses, and Viral DNA Isolation {#s2a}
---------------------------------------

TT (752-1) was provided by the National Vaccine and Serum Institute, Beijing. NYCBH strain was provided by the AIDS Research and Reference Reagent Program (Catalog number 3929) of the U.S. National Institutes of Health. Both viruses were grown in CEF prepared from 9 to 11 day-old embryonic chicken eggs and cultured in Eagle's medium supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% antibiotic at 37°C in a 5% CO~2~ atmosphere. TT clones were isolated from TT (752-1) by plaque-purifications at terminal dilutions. Seven viral plaques were isolated and amplified by sequential four rounds of passages to produce enough material for sequencing [@pone.0060557-Qin1]. Plaque images ([Fig. S1](#pone.0060557.s001){ref-type="supplementary-material"}) were processed with ImageJ (National Institutes of Health) [@pone.0060557-Abramoff1]. Genomic DNA of each clone was extracted and purified using proteinase K digestion followed by phenol-chloroform extraction as described previously [@pone.0060557-Rice1].

Genome Sequencing, Assembly, and Annotation {#s2b}
-------------------------------------------

The genomes of TT clones were sequenced by Illumina Hiseq2000 Sequencer (Illumina Inc, CA) using shotgun sequencing of 500 bp paired-end sequencing library. Contigs were assembled and scaffolds were constructed using raw data with SOAP denovo and SOAP aligner (Beijing Genomics Institute) [@pone.0060557-Li1]. GenBank BLAST searches were performed for all scaffolds and sequences derived from the host genome were removed. The resulting alignments were analyzed by BioEdit (Ibis Bioscience, CA) and Contigexpress (Informax Inc, MD) to identify gaps between scaffolds. The average size of sequencing reads was 90 bp. Sequence gaps were present in the genome especially in ITRs. They were subsequently filled by polymerase chain reaction and Sanger sequencing.

Genome Annotation Transfer Utility (GATU) [@pone.0060557-Tcherepanov1] was used to analyze ORFs in TT genomes using VACV-Copenhagen (Cop) as the reference. Orthologs and unassigned ORFs (i.e., ORFs that had no ortholog in Cop) were identified. ORFs shorter than 50 amino acids (aa) or without orthologous gene were excluded from the analysis. Unassigned ORFs of 50 aa or longer was categorized as OPVs genes according to the GenBank BLAST result with the highest similarity [@pone.0060557-Altschul1]. Viral Genome Organizer [@pone.0060557-Upton2] was used to analyze the positions of individual genes. Sequences of ORFs with polymorphisms including frame-shift insertion or deletion among TT clones were further confirmed by Sanger sequencing**.** In cases where an ORF contained more than one start codon (ATG) near the 5′ terminal, BLAST was conducted to compare the orthologous sequences in other VACVs. The most frequently used ATG was selected as the tentative ORF in TT.

Phylogenetic Analysis {#s2c}
---------------------

BioEdit was used to produce alignments of multiple genomes by Clustal W method [@pone.0060557-Thompson1], and Base-By-Base software (<http://athena.bioc.uvic.ca/virology-ca-tools/base-by-base/>) [@pone.0060557-Brodie1], [@pone.0060557-Esteban1] was used to trim the alignments and produce a visual summary of whole genome alignments. Phylogenetic analysis was carried out using the alignments of the conserved central region of 160.4 kb DNA sequences between the two ITRs starting from TT_025 and ending with TT_255. This region in TT corresponded with the orthologous region between C7L and B16R in Cop. Global gaps (the gap regions present in more than half of these aligned genomes) [@pone.0060557-Garcel2] were removed from the alignments. Phylogenetic analysis was performed using a maximum-likelihood analysis with general time-reversible (GTR) substitution model, subtree-prune-and-regraft (SPR) improvement, and 1000 bootstrap replicates (<http://www.atgc-montpellier.fr/phyml/>). The phylogenetic tree was visualized using Figtree (<http://tree.bio.ed.ac.uk/software/figtree/>). MEGA 5 [@pone.0060557-Tamura1] was used to calculate pairwise distances between genomes by a Kimura 2-parameter substitution model including transition and transversion substitutions and pairwise-deletion treatment. The average values of pairwise distances between TT or Dryvax clones were calculated to illustrate the sequence diversity within these two groups of viruses. The standard deviation (σ) of each group was computed.

Genomic Sequence Orthology {#s2d}
--------------------------

To analyze the genomic sequence orthology among TT clones, a consensus sequence was first derived. TT11 had the highest similarity to the consensus sequence and was therefore chosen as the reference. ORFs of TT11 were compared with orthologous ORFs of four other TT clones and other VACV genomes to calculate the full-length nucleotide sequence similarity using GATU and DNAMan (Lynnon Corporation, Quebec, Canada).

Nucleotide Sequence Accession Numbers {#s2e}
-------------------------------------

The full genomic sequences of five TT clones were deposited in GenBank with accession numbers from JX489135 to JX489139. The OPVs used in this report and their GenBank accession numbers are listed in [Table S1](#pone.0060557.s002){ref-type="supplementary-material"}. TT-TW, a variant of TT (752-1) without plaque-purification was sequenced in this laboratory in 2010 (unpublished).

Mouse Brain Based Neurovirulence Determination {#s2f}
----------------------------------------------

TT viruses and the NYCBH strain were serially diluted in phosphate buffered saline (PBS) and then 3 x 10^2^ plaque forming units (PFU) in 30 µl PBS were inoculated intracranially to groups of five 3-week old female BALB/c mice anesthetized with 1.25% 2,2,2-tribromoethyl alcohol. Body weights and mortality were recorded daily during the 12-day observation period.

Rabbit Skin Virulence Determination {#s2g}
-----------------------------------

TT clones and the NYCBH strain were serially diluted from 10^6^ to 10^2^PFU/ml in PBS. For each viral dilution, two rabbits were tested. Each rabbit received two dorsal skin intradermal inoculations with 0.1 ml viral preparation per injection site. At day 4 post-infection (p.i.), the diameters of lesions were measured and the incidence of putrescence was recorded.

Ethics Statement {#s2h}
----------------

All experiments were conducted in accordance with the guidelines of the Laboratory Animal Center of Chinese Center for Disease Control and Prevention and NCAIDS. All procedures involving animal use and care were approved by the Institutional Committee on Laboratory Animals of NCAIDS.

Results {#s3}
=======

Clone Isolation and Genome Assembly {#s3a}
-----------------------------------

Seven randomly selected TT clones were isolated by plaque picking at the terminal dilution on CEF cells and amplified. The sizes of plaques varied after initial runs of plaque picking of each clone. No obvious difference was observed between the plaque sizes of the clones following passage and those of the original vaccine pool, although the average plaque sizes of TT9 and TT11 were significantly smaller (p\<0.05) than those of TT7 and TT8 ([Fig. S1](#pone.0060557.s001){ref-type="supplementary-material"}).

All seven viral genomic DNAs were sequenced and their contigs were assembled. All the assemblies were aligned with Cop and ListerV107 to accurately identify any gaps, particularly in highly repeated elements such as the ITRs. Five TT clones (TT8 to TT12) were successfully assembled and generated full genomic sequences of 189,366 to 191,144 bp. Two clones, TT6 and TT7 had small gaps in the two ITRs and thus did not yield full genomic sequences.

Phylogenetic Analysis {#s3b}
---------------------

We examined the phylogenetic relationship of various OPVs by maximum-likelihood method using alignments of the conserved 160.4 kb central region (i.e., the ITR sequences were excluded) ([Fig.1](#pone-0060557-g001){ref-type="fig"}). These sequences included five TT plaque-purified clones, TT-TW, and 25 other commonly known OPVs including 11 Dryvax clones DPPs ([Table S1](#pone.0060557.s002){ref-type="supplementary-material"}). Although TT6 and TT7 clones contained incomplete ITRs, the regions used in phylogenetic analysis were complete and thus were included in this analysis.

![Phylogenetic analysis of TT and other OPV strains.\
Phylogenetic relationships between TT-associated strains (including Tian Tan and TT-TW), TT clones (marked by \*), and OPVs including 11 Dryvax clones (marked by \#). Bootstrap values higher than 900 are shown. Names and GenBank accession numbers of the viral strains shown in this figure are listed in [Table S1](#pone.0060557.s002){ref-type="supplementary-material"}. The scale bar of branch length was shown under the phylogenetic tree.](pone.0060557.g001){#pone-0060557-g001}

Notably, TT clones clustered with a bootstrap value of 988 and shared a common ancestry with the TT genomic strain (AF095689.1) published in 1998 and another TT (752-1) derived TT-TW sequenced in 2010. Among the other VACVs, Cop was most similar to the TT cluster and HSPV-MNR76, NYCBH/Dryvax-derived DPP clones, Acam2000 and Duke exhibited least similarity. Among the analyzed OPV sequences, ectromelia virus strain Moscow (ECTV-Mos) was most distant from the TT cluster.

All the Dryvax derived strains clustered as one group, including the Dryvax clones (DPPs), Acam2000 that were independently isolated from another stock of the same vaccine, and Duke that isolated from a patient experiencing a Dryvax vaccine-associated complication. The TT clones exhibited higher sequence diversity than the Dryvax clones. The average value of pairwise distances between TT clones was 0.00401 (σ = 0.00026) and the average value between Dryvax clones was 0.00294 (σ  = 0.00017).

Gene Annotations and Polymorphisms in Nucleotide Sequence {#s3c}
---------------------------------------------------------

ORFs longer than 50 aa were initially annotated as genes and those without comparable orthologs in other OPVs were removed from annotation. Small ORFs that embedded in larger ORFs in the genomes of other poxviruses and those found to be truncated or split into two or more portions were removed from the ORF list and reclassified as "fragments". Six such fragments were identified: TT_005.1, TT_028.1, TT_191.1, TT_210.1, TT_252.1, and TT_265.1. The genomic organizations of TT clones were identical to other sequenced VACVs. There were 255 unique ORFs in the genome and nine duplicated ORFs (TT_001 to TT_009 and TT_261 to TT_269) in ITRs. There are 273 ORFs found in each of the TT clones ([Table S2](#pone.0060557.s003){ref-type="supplementary-material"}), including orthologs of four additional conserved ORFs which were recently recognized in Cop and WR. These conserved ORFs have a ".5″ in their names.

The orthology between TT clones was further assessed through the distribution of polymorphic sites. We first generated a consensus sequence using the most frequent nucleotide from each position. The similarities of each TT clone varied from 97.36% to 98.30% and TT11 had the highest similarity with the consensus ([Fig. 2](#pone-0060557-g002){ref-type="fig"}). The ORFs derived from TT11 were thus used as the reference for full-length ORF comparisons among TT clones ([Table S3](#pone.0060557.s004){ref-type="supplementary-material"}). Among the 273 annotated ORFs, the DNA sequences of 241 ORFs in four other TT clones had \>95% identity with those in TT11. Conserved ORFs were located in the middle of the viral genome with gene functions related to viral replication and structure. For the remaining 32 ORFs, there was at least one clone displaying \<95% identity with the reference ORF. More than 95% of the polymorphic ORFs exhibited length variations due to the acquisition of one or more point mutations, in-frame insertions or deletions. ORFs with relatively low similarity were located near ITRs where many virulence or immunomodulation-associated proteins reside.

![Distribution of polymorphic sites in TT genomes.\
The genomes were aligned by BioEdit and edited using Base-by-Base software. A consensus sequence was generated from TT8 to TT12 by Base-By-Base software. Sites in TT clones different from the consensus sequence are displayed in blue for nucleotide substitutions, green for insertions, and red for deletions. The extent of similarity (%) of each clone with the consensus sequence is displayed.](pone.0060557.g002){#pone-0060557-g002}

[Table 1](#pone-0060557-t001){ref-type="table"} summarizes the major ORF differences among TT clones and four reference VACVs including Cop, ListerV107, WR, and Acam2000. Four ORFs (TT_147, TT_185, TT_188, and TT_190) in the TT genomic sequences had orthologs in TT genome (AF095689.1) and thus were annotated, but corresponding sequences in the reference genomes were not annotated. Whether these ORFs code for functional proteins remains to be investigated. Two ∼4 kb regions in TT strains (ORF TT_011 to TT_019 and TT_184 to TT_190, encoding host defense modulators, ankyrin-like proteins, and A-type inclusion protein) had orthologous regions in Acam2000 and WR, but were absent in Cop. Conversely, the regions coding three ORFs (C19L, C20L and C21L) in the ITRs of Cop were absent in TT genomes.

10.1371/journal.pone.0060557.t001

###### Gross differences in ORF size (nt) and complement.

![](pone.0060557.t001){#pone-0060557-t001-1}

                                                                                                                                 Gene Size (bp)                                                   
  ---------------------- ------------------------------------------------------------------- ---------------------------------- ---------------- ------ ------ ------ ------ ------ ------ ------ ------
  VACV_TT_001 (ITR)^a^                        Chemokine binding protein                         VACWR001/218, Cop-C23L/B29R           720         726    720    735    729    735    777    726    735
  VACV_TT_003 (ITR)                           TNF alpha receptor (CrmB)                         VACWR004/215, Cop-C22L/B28R           438         369    438    360    429    369    369    369    369
  VACV_TT_004 (ITR)                             Ankyrin-like protein                                   Cop-C18L/B24R                  360         360    363    453    597    453    438    597   
  VACV_TT_005 (ITR)                             Ankyrin-like protein                                   Cop-C17L/B23R                  540         735    1134   549    1140   1161   1275   1149  
  VACV_TT_005.1 (ITR)                           Ankyrin-like protein                                   Cop-C17L/B23R                                            492                               
  VACV_TT_006 (ITR)                                  Unknown ^b^                                       Cop-C16L/B22R                  546         546    546    546    546    546    444    546   
  VACV_TT_007 (ITR)                                    Unknown                                         Cop-C15L/B21R                  210         210    210    210    210    276    270    270   
  VACV_TT_008 (ITR)                               EGF growth factor                                VACWR009/210, Cop-C11R             423         426    423    426    426    429    423    420    423
  VACV_TT_009 (ITR)                           IL-1 receptor antagonist                             VACWR010/209, Cop-C10L             996         996    996    996    996    996    996    996    996
  VACV_TT_011                Zinc finger-like protein, apoptosis, host defense modulator      VACWR011/208, VARBSH-D6R/005 ^c^        252         252    363    153    252           543    252    546
  VACV_TT_012                Zinc finger-like protein, apoptosis, host defense modulator        VACWR012/207, VARBSH-D6R/005          189         189    189    189    189           201    189    189
  VACV_TT_013              Soluble IL-18 binding protein (Bsh-D7L), host defense modulator        VACWR013, VARBSH-D7L/006            381         381    381    381    381           381    375    381
  VACV_TT_014             Ankyrin-like protein (Bang-D8L), 77 kDa cowpox host-range protein      VACWR014, CPXVBR-V024 ^d^            273         273    273    273    273                  273    714
  VACV_TT_015             Ankyrin-like protein (Bang-D8L), 77 kDa cowpox host-range protein        VACWR014, CPXVBR-V024              429         429    933    429    429           429    429   
  VACV_TT_016             Ankyrin-like protein (Bang-D8L), 77 kDa cowpox host-range protein        VACWR015, CPXVBR-V024              192         426           414    399                  408    414
  VACV_TT_017             Ankyrin-like protein (Bang-D8L), 77 kDa cowpox host-range protein        VACWR016, CPXVBR-V024              234         234    234    234    234           234    234    234
  VACV_TT_018             Ankyrin-like protein (Bang-D8L), 77 kDa cowpox host-range protein        VACWR017, CPXVBR-V024              216         216    216    216    216                  216    216
  VACV_TT_019                                          Unknown                                  VACV-Lister_VACV107-List015           180         180    180    180    180           180          
  VACV_TT_020                                   Ankyrin-like protein                                 VACWR019, Cop-C9L                1905        1905   1899   1905   1905   1905   1905   1905   1905
  VACV_TT_022                                          Unknown                                       VACWR020, Cop-C8L                534         534    534    534    534    555    534    534    534
  VACV_TT_025                                Host range virulence factor                             VACWR021, Cop-C7L                453         453    453    453    453    453    453    453    453
  VACV_TT_026                                          Unknown                                       VACWR022, Cop-C6L                456         363    456    456    456    456    456    456    456
  VACV_TT_027                                    Kelch-like protein                                  VACWR023, Cop-C5L                615         615    561    615    615    615    615    615    615
  VACV_TT_028                                 IL-1 receptor antagonist                               VACWR024, Cop-C4L                951         570    387    594    951    951    951    189    951
  VACV_TT_028.1                               IL-1 receptor antagonist                               VACWR024, Cop-C4L                                   189                                      
  VACV_TT_029                            Secreted complement binding protein                         VACWR025, Cop-C3L                792         786    786    792    792    792    792    792    792
  VACV_TT_031                                    Kelch-like protein                                  VACWR026, Cop-C2L                1539        1539   1539   1539   1539   1539   1539   1521   1539
  VACV_TT_032                                          Unknown                                       VACWR027, Cop-C1L                675         675    675    690    675    675    675    675    690
  VACV_TT_035                                   Ankyrin-like protein                                 VACWR030, Cop-M1L                1413        1413   1413   1413   1413   1419   1413   1410   1419
  VACV_TT_036                                      NF-κB inhibitor                                   VACWR031, Cop-M2L                663         663    663    663    663    663    663    663    663
  VACV_TT_038                        Serpin (serine protease inhibitor) (SPI-3)                      VACWR033, Cop-K2L                1110        1110   1110   1110   1110   1110   1110   1110   1110
  VACV_TT_041                       IFN resistance, elF2 alpha-like PKR inhibitor                    VACWR034, Cop-K3L                267         267    267    267    267    267    267    267    267
  VACV_TT_043                                   Monoglyceride lipase                                 VACWR037, Cop-K5L                366         366    366    366    366    411    528    411    405
  VACV_TT_044                                   Monoglyceride lipase                                 VACWR038, Cop-K6L                255         246    246    255    255    246    246    246    246
  VACV_TT_046                      Apoptosis inhibitor (mitochondrial-associated)                    VACWR040, Cop-F1L                723         681    681    681    681    681    681    681    681
  VACV_TT_054                                          Unknown                                       VACWR046, Cop-F7L                249         249    249    243    249    279    243    243    243
  VACV_TT_059                                          Unknown                                       VACWR050, Cop-F11L               1065        1065   1065   1065   1065   1065   1065   1047   1047
  VACV_TT_063.5                                      IMV protein                                         VACWR53.5                    150         150    150    150    150                         150
  VACV_TT_065                                          Unknown                                       VACWR054, Cop-F15L               477         477    477    477    477    477    477    477    444
  VACV_TT_071                               IFN resistance, PKR inhibitor                            VACWR059, Cop-E3L                573         573    573    573    573    573    573    573    573
  VACV_TT_073                                    Virosome component                                  VACWR061, Cop-E5R                1026        1026   1026   1026   1026   996    996    570    1026
  VACV_TT_080                                      DNA polymerase                                    VACWR065, Cop-E9L                3021        3021   3021   3021   3021   3021   3021   3018   3021
  VACV_TT_086                                          Unknown                                          CPXVBR-078A                   189         189    189    189    189                        
  VACV_TT_101.5                                 RNA polymerase (RPO7)                               VACWR083, Cop-G5.5R               192         192    192    192    192    192    192    192    192
  VACV_TT_102                      Virulence factor, NIpC/P60 superfamily protein                    VACWR084, Cop-G6R                498         498    498    498    498    498    498    498    498
  VACV_TT_109                                          Unknown                                       VACWR089, Cop-L2R                258         258    258    264    258    264    264    258    264
  VACV_TT_126                                          Unknown                                           CPXVBR-116                   183         183    183    183    183                        
  VACV_TT_147                                          Unknown                                        VACV-TianTan-134                219         219    219    219    219                        
  VACV_TT_151.5             Thioredoxin-like protein, S-S bond formation pathway protein            VACWR121, Cop-A2.5L               231         231    231    231    231    231    231    231    231
  VACV_TT_154                                    39kDa core protein                                  VACWR123, Cop-A4L                852         852    852    846    852    846    846    846    846
  VACV_TT_162                                   IMV Membrane protein                                 VACWR128, Cop-A9L                300         327    312    327    327    300    300    327    327
  VACV_TT_163                            P4a (precursor of core protein 4a)                          VACWR129, Cop-A10L               2679        2679   2679   2679   2679   2676   2676   2676   2676
  VACV_TT_168                                    Structural protein                                  VACWR131, Cop-A12L               576         576    579    576    576    579    579    579    579
  VACV_TT_170.5                        IMV membrane protein, Virulence factor                       VACWR134, Cop-A14.5L              162         162    162    162    162    162    162    162    162
  VACV_TT_180                                Holliday junction resolvase                             VACWR142, Cop-A22R               564         564    564    531    564    531    564    564    564
  VACV_TT_184                              Cowpox A-type inclusion protein                                VACWR146                    639                720    639    720                  465    465
  VACV_TT_185                                          Unknown                                        VACV-TianTan-171                207         207           207    207                        
  VACV_TT_186                              Cowpox A-type inclusion protein                        MPXV_USA2003_044_143 ^e^            162         162    162    162    162                        
  VACV_TT_187                              Cowpox A-type inclusion protein                                VACWR147                    693         693    684    684    693                  684    684
  VACV_TT_188                                          Unknown                                        VACV-TianTan-173                186         186    186    186    186                        
  VACV_TT_189                              Cowpox A-type inclusion protein                                VACWR148                    2178        2178   2178   2178   2178                 2166   2178
  VACV_TT_190                                          Unknown                                        VACV-TianTan-175                183         183    183    183    183                        
  VACV_TT_191                            P4c (precursor of core protein 4c)                          VACWR149, Cop-A26L               1509        1509   1509   609    1509   969    1509   1503   1503
  VACV_TT_191.1                          P4c (precursor of core protein 4c)                          VACWR149, Cop-A26L                                         846                               
  VACV_TT_198                               ATPase, DNA packaging protein                            VACWR155, Cop-A32L               903         813    813    813    813    903    903    813    813
  VACV_TT_207                                          Unknown                                   VACWR161, VARGAR-A43R ^f^            195         195    195    195    195           189    189    189
  VACV_TT_208                                          Unknown                                    VACV-REC_GLV_1h68-225^g^            183         183    183    183    183                        
  VACV_TT_210                                        Semaphorin                                      VACWR163, Cop-A39R               1212        687    687    774    774    1212   1212   399    888
  VACV_TT_210.1                                      Semaphorin                                           VACWR164                                429    468    468    468                  429    429
  VACV_TT_212                        C-type lectin-like type-II membrane protein                     VACWR165, Cop-A40R               480         480    480    480    480    507    480    507    480
  VACV_TT_213                                 Secreted virulence factor                              VACWR166, Cop-A41L               660         660    660    660    660    660    660    660    660
  VACV_TT_216                                          Unknown                                            VACWR169                    237         237    237    237    237           237           237
  VACV_TT_217                               Hydroxysteroid dehydrogenase                             VACWR170, Cop-A44L               1041        1041   1041   1041   1041   1041   1041   1041   1041
  VACV_TT_219                                 IL-1 signaling inhibitor                               VACWR172, Cop-A46R               723         723    723    723    723    645    723    723    723
  VACV_TT_221                                          Unknown                                       VACWR173, Cop-A47L               759         759    759    759    735    735    759    735    759
  VACV_TT_222                                    Thymidylate kinase                                  VACWR174, Cop-A48R               684         684    684    684    684    615    684    615    684
  VACV_TT_228                        Intracellular TLR and IL-1 signal inhibitor                     VACWR178, Cop-A52R               573         573    573    573    573    573    573    573    573
  VACV_TT_229                                          Unknown                                            Cop-A54L                    273                              273    273    258          
  VACV_TT_230                                    TNF receptor (CrmC)                                 VACWR179, Cop-A53R               399         399    561    561    399    312    561    399    312
  VACV_TT_231                                          Unknown                                    VACV-Lister_VACV107-173             180         180    180    180    180           180          
  VACV_TT_232                                    Kelch-like protein                                  VACWR180, Cop-A55R               1695        1695   1695   1695   1695   1695   1695   1695   1695
  VACV_TT_242                               Complement control, CD46, EEV                            VACWR187, Cop-B5R                954         954    954    954    954    954    666    954    954
  VACV_TT_247                                          Unknown                                     VACV-REC_GLV_1h68-269              174         174    174    174    174                        
  VACV_TT_250                                          Unknown                                       VACWR193, Cop-B11R               231         231    231    228    219    267    219    219    219
  VACV_TT_252                                       Serpin 1,2,3                                VACWR195, Cop-B13R, Cop-B14R          1008        351    1008   1008   1008   351    351    381    1038
  VACV_TT_252.1                                     Serpin 1,2,3                                VACWR195, Cop-B13R, Cop-B14R                      669                         669    669    669    1038
  VACV_TT_255                                    IL-1 beta receptor                                  VACWR197, Cop-B16R               873         873    873    873    873    873    981    981    981
  VACV_TT_258                                   Ankyrin-like protein                                 VACWR199, Cop-B18R               1725        1725   1725   1725   1725   1725   1242   1725   1725
  VACV_TT_259                                  IFN alpha/beta receptor                               VACWR200, Cop-B19R               1056        1062   1056   1056   1062   1062          798    1056
  VACV_TT_260                                   Ankyrin-like protein                                      Cop-B20R                    1809        1794   441    1794   1842   384                 
  VACV_TT_261 (ITR)                           IL-1 receptor antagonist                             VACWR010/209, Cop-C10L             996         996    996    996    996                  996    996
  VACV_TT_262 (ITR)                               EGF growth factor                                VACWR009/210, Cop-C11R             423         426    426    426    426                  420    423
  VACV_TT_263 (ITR)                                    Unknown                                         Cop-C15L/B21R                  210         210    210    210    210    276                 
  VACV_TT_264 (ITR)                                    Unknown                                         Cop-C16L/B22R                  546         546    546    546    546    546    444    546   
  VACV_TT_265 (ITR)                             Ankyrin-like protein                                   Cop-C17L/B23R                  540         735    1134   549    1140   1161   1275   1149  
  VACV_TT_265.1 (ITR)                           Ankyrin-like protein                                   Cop-C17L/B23R                                            492                               
  VACV_TT_266 (ITR)                             Ankyrin-like protein                                   Cop-C18L/B24R                  360         360    363    453    597    453           597   
  VACV_TT_267 (ITR)                           TNF alpha receptor (CrmB)                                Cop-C22L/B28R                  438         369    438    360    429    369    369    369    369
  VACV_TT_268 (ITR)                           Chemokine binding protein                         VACWR001/218, Cop-C23L/B29R           720         726    720    735    729    735    777    726    735

Gross differences in ORF size (nt) and complement among TT clones and four VACVs (Cop, ListerV107, Acam 2000, and WR). a: ITR, inverted terminal repeat; b: genes with unknown functions; c: CPXVBR, Cowpox virus Brighton Red; d: VARBSH, Variola major virus Bangladesh; e: MPXV_USA2003_044, monkeypox virus strain USA2003_044; f: VARGAR, variola virus Garcia strain; g: VACV-REC_GLV_1h68, Vaccinia virus strain recombinant GLV-1h68 strain.

Several genes had polymorphic lengths because of the presence of substitution mutations. As shown in [Fig. 3A](#pone-0060557-g003){ref-type="fig"}, the length of ORF TT_210/210.1 (A39R, also known as semaphorin) in TT8 was the same as that in Cop and ListerV107 (1212 bp). In TT9 and TT10, a C685T mutation truncated this ORF to 687 bp and a T774A mutation truncated this ORF to 774 bp in TT11 and TT12 or 888 bp in WR. In another example, shown in [Fig. 3B](#pone-0060557-g003){ref-type="fig"}, the start codons for ORF TT_180 (A22R, Holliday junction resolvase) in TT11 and Cop were altered by a T-A mutation near the 5′ terminal and the next available start codon was 33 bp downstream. This change shortens the size of this ORF to 531 bp. Several polymorphisms were generated by insertions or deletions. One interesting example was the addition of copies of 6 bp repeats (ACAGAT) in TT_250 (B11R, function unknown) ([Fig. 3C](#pone-0060557-g003){ref-type="fig"}). In TT11, TT12, Acam2000, ListerV107, and WR, there was one copy of ACAGAT and in TT8, TT9, and TT10 there were three copies. Nine copies were present in Cop. In addition, in-frame insertions near the 3′ terminal of TT_162 (A9L, intracellular mature virion membrane protein) resulted in ORFs of 327 bp in TT11, TT9, TT12, Acam2000, and WR; 312 bp in TT10; and 300 bp in TT8, Cop, and ListerV107 ([Fig. 3D](#pone-0060557-g003){ref-type="fig"}). TT_230 (A53R, TNF receptor CrmC) in TT8, TT12, Cop, and WR consisted of a 16 bp frame-shift deletion near the 5′ end and a shift of start codon 16 bp upstream from the ones in TT11, TT9, TT10, Acam2000, and ListerV107 ([Fig. 3E](#pone-0060557-g003){ref-type="fig"}).

![Representative nucleotide sequence polymorphisms in five ORFs among TT clones and four reference VACV genomes.\
Nucleotide sequence polymorphisms in ORFs TT_210/210.1 (A39R) (A), TT_180 (A22R) (B), TT_250 (B11R) (C), TT_162 (A9L) (D), and TT_230 (A53R) (E) are shown. The TT11 clone with the highest sequence similarity to the consensus sequence was used as the reference. Altered nucleotides are shown in lower case. Nucleotides identical to TT11 are denoted with "--" and nucleotides not present in TT11 or other strains are denoted with dots. \#\#\#: start codon, \*\*\*: stop codon, R: 6-bp nucleotide repeat, numbers in parenthesis: nucleotide length of the ORF.](pone.0060557.g003){#pone-0060557-g003}

Polymorphisms in Virulence Reaction Associated Proteins {#s3d}
-------------------------------------------------------

VACV contains more than 200 genes, some of which have been previously reported to be associated with viral virulence and immunomodulation. We selected seven virulence reaction-associated genes from TT clones and Acam2000 for amino acid sequence comparison ([Table 2](#pone-0060557-t002){ref-type="table"}). Acam2000 was a clonal Vero cell culture vaccinia virus derived from NYCBH/Dryvax, and its relative gene sequences were selected to represent those of the NYCBH strain used in the our study. TT_213 (A41L) was a secreted virulence factor and its deletion was reported to result in severe lesions and increased viral clearance in the mouse skin model [@pone.0060557-Ng1]. Six amino acid polymorphic sites were found in TT clones and Acam2000. TT clones displayed a substitution mutation, K122E, located in the chemokine binding protein superfamily conserved domain. The change from alkaline lysine (K) to glutamic acid (E) residue might be associated with the attenuation of TT. Seven polymorphic sites were found in TT_242 (B5R) among TT clones. B5R was a type I integral membrane glycoprotein and extracellular enveloped virion (EEV) complement control protein which blocked complement activation and associated inflammatory responses. Destruction of B5R was reported to contribute to attenuation of VACV [@pone.0060557-Morikawa1], [@pone.0060557-Isaacs1]. There were three substitution mutations among TT clones and Acam2000, L55S, V82I and I153M. L55S changed the polarity of the amino acid.

10.1371/journal.pone.0060557.t002

###### Mutations identified in the seven virulence-associated proteins.

![](pone.0060557.t002){#pone-0060557-t002-2}

  Gene Name    Protein Size (aa)           Protein Function (Ortholog in Cop)            Non-Synonymous site^a^   Acam2000     TT8         TT9      TT10      TT11      TT12
  ----------- ------------------- ----------------------------------------------------- ------------------------ ---------- ---------- ----------- ------- ----------- -------
  TT_025              150                      Host range virulence factor                         31              K ^b^        --         --        --       K31R       --
                                                        (Cop-C7L)                                  38                D          --         --        --       D38G      D38G
                                                                                                   41                K          --         --        --        --       K41Q
                                                                                                  130                N          --         --        --        --       N130T
  TT_102              165                      Virulence factor, NIpC/P60,                         90                N         N90D       N90D      N90D      N90D      N90D
                                              superfamily protein (Cop-G6R)                       105                N        N105D       N105D      --        --        --
                                                                                                  115                E        E115D       E115D     E115D     E115D     E115D
                                                                                                  122                I        I122V       I122V     I122V     I122V     I122V
                                                                                                  123                D        D123E       D123E     D123E     D123E     D123E
  TT_170.5            53           IMV membrane protein, virulence factor (Cop-A14.5L)             52                A          --        A52V      A52V       --        --
  TT_213              219                       Secreted virulence factor                          5                 L          --         L5V       L5V       --        --
                                                       (Cop-A41L)                                  7                 I          --         I7V       I7V       --        --
                                                                                                   47                H          --      H47P ^c^    H47P      H47P      H47P
                                                                                                  122                K        K122E       K122E     K122E     K122E     K122E
                                                                                                  160                D          --         --        --        --       D160N
                                                                                                  178                A          --      A178T ^c^   A178T     A178T     A178T
  TT_242              317                       Complement control, CD46,                          40                N         N40D       N40D       --       N40D      N40D
                                                      EEV (Cop-B5R)                                41                N         N41K       N41K       --       N41K      N41K
                                                                                                   55                L       L55S ^c^     L55S      L55S      L55S      L55S
                                                                                                   82                V         V82I       V82I      V82I      V82I      V82I
                                                                                                  140                C          --        C140Y      --       C140Y     C140Y
                                                                                                  153                I        I153M       I153M     I153M     I153M     I153M
                                                                                                  216                I          --         --        --     I216T ^c^   I216T
  TT_245              182                        Virulence, ER resident                            15                L          --         --        --       L15V      L15V
                                                        (Cop-B7R)                                 104                R        R104K       R104K      --       R104K     R104K
                                                                                                  168                D        D168N        \-        --        --        --
  TT_248              77                       Virulence factor (Cop-B9R)                          54                R       R54L ^c^      \-        --        --        --
                                                                                                   59                G         G59E        \-        --        --        --

Mutations identified in the seven virulence-associated proteins in five TT clones and Acam2000. Acam 2000 is used as the reference. Amino acid (aa) in TT clones identical to the reference is shown as "--". a: amino acid position in Acam2000; b: single letter aa code; c: aa mutation resulted in polarity change. Abbreviations, IMV: intracellular mature virion, EEV: extracellular enveloped virion, ER: endoplasmic reticulum.

Six immunomodulation-associated genes were also selected for closer examination ([Fig. 4](#pone-0060557-g004){ref-type="fig"}). TT_210 (A39R) encoded a semaphorin influencing the outcome of dermal infection and, when truncated, the protein product could not be exported extracellularly [@pone.0060557-Gardner1]. Presence of a stop codon in the central sema domain yielded a truncated product of 228 aa in TT9 and TT10; and 257 aa in TT11 and TT12 ([Fig. 4A](#pone-0060557-g004){ref-type="fig"}). Truncation of the protein was also observed in Acam2000, with a product of 134 aa. TT_255 (B16R) encoded an IL-1 beta receptor. It was 290 aa in length in Cop and all five TT strains. It was longer in Acam2000 due to the presence of additional N-terminal 36 aa ([Fig. 4B](#pone-0060557-g004){ref-type="fig"}). TT_259 (B19R) encoded interferon-α/β receptor. In Cop, TT9, and TT12, it was 352 aa in length. There was a 2-aa deletion (Ser-Leu) in TT8, TT9, and TT10 near the N-terminus ([Fig. 4C](#pone-0060557-g004){ref-type="fig"}). In Acam2000, B19R was 265 aa and lost the immunoglobulin domain near the C-terminal. TT_028 (C4L) encoded IL-1 receptor antagonist and was 316 aa in length in Cop, TT8, and TT12 ([Fig. 4D](#pone-0060557-g004){ref-type="fig"}). It was shorter in TT9, TT10 and TT11 due to the deletion of 120 aa in N-terminal. In Acam2000, C4L was split into three fragments. TT_230 (A53R) encoded TNF receptor (CrmC) and its length differed greatly among these genomes ([Fig. 4E](#pone-0060557-g004){ref-type="fig"}). It was 102 aa in Cop and was 30 aa longer in TT8, TT9, TT12, and Acam2000. In TT10 and TT11, there was a 84 aa elongation in the C-terminal. Two forms of N-terminal sequences were present in A53R as described earlier. TT_252 (B13R) encoded serine protease inhibitors (Serpin 1, 2, 3) and was 116 aa in length in both Cop and TT9 ([Fig. 4F](#pone-0060557-g004){ref-type="fig"}). It was 335 aa in four other TT clones due to the presence of additional C terminal 219 aa. In Acam2000 it was 126 aa due to the presence of an additional N-terminal 10 aa.

![Major polymorphisms within immunomodulation-associated proteins in TT clones, Acam2000, and Cop.\
Six proteins previously known to be associated with immunomodulation were selected for comparison using Cop as the reference strain. These proteins are A39R encoding semaphorin (A), B16R encoding an IL-1 beta receptor (B), B19R encoding a soluble and cell-surface interferon- α/β receptor (C), C4L encoding an IL-1 receptor antagonist (D), A53R encoding TNF receptor CrmC (E), and B13R encoding serine protease inhibitors (Serpin 1, 2 and 3) (F). Special functional domains of proteins are depicted. Premature terminations are shown as solid triangles. Locations of insertions and deletions are also shown.](pone.0060557.g004){#pone-0060557-g004}

Virulence of TT Clones and NYCBH in Animal Models {#s3e}
-------------------------------------------------

We compared the neurovirulence of parental TT (752-1), TT clones, and NYCBH. Groups of three-week-old BALB/c mice were intracranially inoculated with 3 x 10^2^ PFU viral preparations or PBS and observed daily for weight change and mortality. In the control group (injected with PBS), all mice gained weight over the 12-day observation period. Mice that received NYCBH showed severe signs of illness, weight loss ([Fig. 5A](#pone-0060557-g005){ref-type="fig"}), and decreased physical activity starting on day 3 p.i. One mouse died on day 4, three more died on day 5 ([Fig. 5B](#pone-0060557-g005){ref-type="fig"}). By day 5, the remaining mouse had lost 39.7% of its initial body weight and died at day 6. For the TT (752-1) group, there was an initial weight gain, but on day 3 the mice began showing weight loss that persisted to day 11. One mouse died on day 7, another on day 8. The remaining three mice survived and gained body weight. The weight change among mice infected with TT (752-1) was less than those infected with NYCBH (P\<0.05).

![Viral neurovirulence properties in mice with intracranial inoculation.\
BALB/c mice (n = 5 per testing group) were inoculated with 3 x 10^2^ PFU of NYCBH, TT (752-1) or five TT clones (TT8 to TT12). Body weights and mortality were monitored daily for 12 days. Average body weight change (%) and one standard deviation (vertical bar) were calculated by comparing the body weight pre- and post-inoculation. Body weight change (A) and mortality (B) in TT (752-1), NYCBH, and PBS control; and body weight change (C) and mortality (D) in five TT clones. Symbols in (A) and (B): PBS: (□), TT (752-1): (○), NYCBH: (♦). Symbols in (C) and (D): TT8: (◊), TT9: (▾), TT10: (•), TT11: (▵), TT12: (×).](pone.0060557.g005){#pone-0060557-g005}

We examined the virulence of five TT clones in the same manner. The patterns of weight loss ([Fig. 5C](#pone-0060557-g005){ref-type="fig"}) and mortality ([Fig. 5D](#pone-0060557-g005){ref-type="fig"}) were similar to their parental strain, but differences among clones were observed. Mice injected with TT8 or TT10 lost 33% of their body weight by day 8 and all of them died on day 9. One of the mice injected with TT12 lost 32% of its body weight, but survived to day 12. Three and four of the mice injected with TT9 and TT11, respectively, initially lost weight but survived and regained body weight up to the original level.

We further characterized the skin virulence of the parental and cloned strains by inoculating four viral preparations, 10^2^ to 10^5^ PFU, into rabbit dorsal skin. Viral virulence was quantified by the diameter of skin lesion on day 4 p.i. As shown in [Table 3](#pone-0060557-t003){ref-type="table"}, among the viral strains tested, NYCBH produced the largest lesions with the largest lesion measuring 9.8 mm in diameter at 10^5^ PFU. Among TT strains, the parental strain yielded the largest lesions at the dilution of 10^5^ PFU (4.6 mm) followed by TT8 (4.2 mm), TT9 (3.4 mm), TT10 (3.4 mm), TT12 (1.2 mm), and TT11 (1.0 mm). NYCBH yielded 100% putrescence at all dilutions. TT clones yield 100% putrescence at the highest 10^5^ PFU inoculation, much less putrescence at the 10^4^ PFU inoculation, and no putrescence at the 10^3^ PFU inoculation.

10.1371/journal.pone.0060557.t003

###### Viral skin virulence in rabbits.

![](pone.0060557.t003){#pone-0060557-t003-3}

                10^5^ PFU   10^4^ PFU   10^3^ PFU   10^2^ PFU                    
  ------------ ----------- ----------- ----------- ----------- ----- ----- ----- -----
  TT8              4.2         100         3.0         50        0     0     0     0
  TT9              3.4         100          0           0        0     0     0     0
  TT10             3.4         100         1.7         75        0     0     0     0
  TT11             1.0         100         0.8         50        0     0     0     0
  TT12             1.2         100         0.9         25        0     0     0     0
  TT (752-1)       4.6         100         4.1         50        0     0     0     0
  NYCBH            9.8         100         6.7         100      5.2   100   4.0   100

Viral skin virulence in rabbits with intradermal inoculation. Rabbits were inoculated intradermally in dorsal skin with 10^2^ to 10^5^ PFU viral preparations from five TT clones, parental TT (752-1), and NYCBH. The average lesion diameter (mm) and putrescence incidence percentage are shown.

Discussion {#s4}
==========

Similar to most vaccinia viruses used in the last century, TT has a vague origin and passage history. The earliest record shows its ancestral strain was isolated from skin lesions of a Chinese individual with smallpox in 1926 [@pone.0060557-Dong1], [@pone.0060557-Lu1], [@pone.0060557-Kai1]. Vaccine stocks were established after monkey-rabbit-bovine passages and were later widely used in China during the smallpox eradication campaign. After 1969, TT vaccines were produced in CEF cell cultures but were never plaque-cloned. The lack or loss of well-organized records for vaccine production further add to the confusion of the identity and lineage of the virus [@pone.0060557-Henderson2]. Here we successfully characterized full genomes of five TT clones isolated from a CEF-derived stock, TT (752-1). Sequences from two other clones with incomplete terminal ITRs were also obtained. Our study, analogous to an earlier genetic analysis [@pone.0060557-Yu1], shows that TT was a vaccinia virus, not a variola virus. Phylogenetic tree analysis shows that all TT clones were a mixture of closely clustered quasi-species with an inter-clone diversity slightly higher than that observed in clones derived from NYCBH/Dryvax. Presence of quasi-species was also reported in Lister/Elstree vaccine strains [@pone.0060557-Weltzin1], [@pone.0060557-Morikawa1], [@pone.0060557-Monath1].

The genome structure of TT is the same as other vaccinia viruses. The genome length of TT clones varied from 189,366 in TT8 to 191,144 in TT11 with 273 identifiable ORFs. Insertions, deletions, and point mutations were present throughout the genome resulting in protein alterations. ORFs located in the middle of the genome were more conserved than those located at the two ITRs. We also examined biological activities of TT strains in mice using intracranial injections. TT (752-1) and its progeny clones behaved different in the induction of weight loss and mortality. These biological variations among TT clones may not be due to the replication abilities since they were similar in our study (data not show). The severity of the weight loss and mortality was less than that produced by the NYCBH strain. Our finding differs from Marennikova et al. who reported that TT displayed higher pathogenicity than NYCBH in mice [@pone.0060557-Polak1], [@pone.0060557-Marennikova1]. The TT stock used by Marennikova et al., was calf skin-derived, not one of the CEF-derived viral strains generated after 1969. We did not examine a calf skin-derived strain in our study and thus direct comparison between the calf skin and CEF derived TT viruses could not be made. Using NYCBH as the common denominator in both studies, it appears passage in CEF might have attenuated the virulence of the calf skin-derived TT. Likewise, we found TT strains displayed less virulence than NYCBH in mice and rabbits. This finding is corroborated by historic data. The frequency of post vaccination encephalitis from CEF-derived TT was 2.1 cases/million for primary vaccinations and 0 for progressive vaccinia; the corresponding data from calf skin-derived NYCBH were 2.9∼12.3 and 0.9∼1.5, respectively [@pone.0060557-Fenner1], [@pone.0060557-The2]. Further systemic genotypic and phenotypic comparison might reveal underlying mechanisms related to viral virulence and immunomodulation.

Our present genomic and phenotypic characterization of TT strains yields valuable information for continuing TT-based research in China or elsewhere to produce safer and more effective smallpox vaccines. It is also useful for the current vaccine research using TT-based vectors for HIV and other pathogenic viruses.

Supporting Information {#s5}
======================
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**Plaque properties of TT (752-1) and seven TT clones.** Each clone of the TT (752-1) was plaque-purified and ∼50 PFU of each clone was plated on a monolayer of CEF cells. The infected cells were cultured for 3 days and then stained with crystal violet and imaged. The plaques were visualized using ImageJ and their sizes were determined.

(TIF)
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Click here for additional data file.
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Identities and GenBank accession numbers of orthopoxviruses cited in this work.
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Click here for additional data file.

###### 

**Complete complement of genes and gene fragments encoded by TT clones.** a: The orthologs in Cop and WR were used as the reference. When no ortholog was present in these two reference strains the gene with the highest similarity in OPVs was used. b: orthologs of \"X_ORF_X\" in Cop were annotated in TT clones. These genes were predicted not to express. c: TT_005.1, TT_028.1, TT_191.1, TT_210.1, TT_252.1, and TT_265.1 were identified as fragments.
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Click here for additional data file.

###### 

**Full length similarities among nucleotide sequences of orthologs in TT clones and four reference strains to TT11.** TT11 was used as the reference clone for comparison with TT8, TT9, TT10, TT12, and four other VACVs (Cop, ListerV107, Acam2000 and WR).

(DOC)
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Click here for additional data file.
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